Orforglipron: Obesity Treatment GLP-1 Receptor Agonist
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals...
- The SELECT trial specifically focused on adults with obesity (BMI of 27 or higher) *and* pre-existing cardiovascular disease - such as a history of heart attack,stroke,or peripheral artery...
- The study found that 6.5% of participants in the semaglutide group experienced a major adverse cardiovascular event (MACE) compared to 5.8% in the placebo group.
Ozempic and cardiovascular Risk: New Findings Demand Closer scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death - in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic). The study, involving over 17,600 participants, showed a statistically significant, though relatively small, increase in these events compared to a placebo group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Understanding the SELECT Trial: Participants and Methodology
The SELECT trial specifically focused on adults with obesity (BMI of 27 or higher) *and* pre-existing cardiovascular disease – such as a history of heart attack,stroke,or peripheral artery disease. participants were randomly assigned to receive either 2.4 mg of semaglutide weekly or a placebo, in addition to their standard cardiovascular care.The primary outcome was the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The median follow-up period was 17.6 months.
| characteristic | Semaglutide Group (n=8831) | Placebo Group (n=8801) |
|---|---|---|
| Median Age, years | 61.3 | 61.3 |
| Female, % | 41.8 | 41.8 |
| History of Myocardial Infarction, % | 28.4 | 28.4 |
| History of Stroke, % | 18.6 | 18.6 |
The Numbers: What the Data Reveals
The study found that 6.5% of participants in the semaglutide group experienced a major adverse cardiovascular event (MACE) compared to 5.8% in the placebo group. While this difference of 0.7% may seem small, it reached statistical importance (hazard ratio 1.13,95% confidence interval 1.01 to 1.26). Importantly, the study also observed a higher rate of reported kidney disease progression in the semaglutide group.
What Does This Mean? Implications for Patients and Doctors
these findings don’t necessarily mean Ozempic is universally dangerous.The increased risk was observed in a *specific* population: those with established cardiovascular disease. For individuals using semaglutide for weight loss without pre-existing heart conditions, the risk profile may remain favorable. However, this study necessitates a more cautious approach to prescribing semaglutide to patients with known cardiovascular issues.